High expression of ATAD2 has previously been found to be associated with an unfavorable prognosis in breast, lung, and prostate cancers and it has been suggested that ATAD2 contributes to the development of aggressive cancer through linking of the E2F and MYC pathways [9], [10], [11]. This evidence concerns the gene MYC and prostate carcinoma.